The open letter, signed by 150 organizations, to the Senate HELP committee on medical innovations legislation (The Cancer Letter, April 29, 2016).
Fitzpatrick Letters: FDA's letter on inspections of hospitals on adverse outcomes reporting, and Rep. Mike Fitzpatrick's (R-Pa.) letter to Vice President Joe Biden on medical device safety regulations, the Cancer Moonshot and the FDA Oncology Center of Excellence (The Cancer Letter, April 15, 2016).
The FDA's order granting PneumoLiner Class II device classification (The Cancer Letter, April 8, 2016).
Amy Reed's consent form for her power morcellation procedure at Brigham and Women's Hospital (The Cancer Letter, April 8, 2016).
The Centers of Medicare and Medicaid Services' transmittal describing its experiment that would alter ASP payment based on ZIP code, and a letter from oncology groups opposing the experiment (The Cancer Letter, March 4, 2016).
The complaint filed by Pharmaceutical Research and Manufacturers of America against HHS and HRSA (The Cancer Letter, Oct. 24, 2014).
The review committee's report recommending the closing of the Indiana University Health Proton Therapy Center (The Cancer Letter, Oct. 17, 2014).
The Pharmaceutical Research and Manufacturers of America's (PhRMA) lawsuit against the Department of Health & Human Services/Health Resources and Services Administration for its 340B "interpretive" rule on the Affordable Care Act orphan drug exclusion (The Cancer Letter, Oct. 10, 2014).
The legal files regarding the DOJ prosecutions of those involved with the supply chain moving counterfeit Avastin into the United States (The Cancer Letter, Oct. 3, 2014).
The April 2006 letter sent from William McGivney to Genentech CEO Art Levinson (The Cancer Letter, Oct. 3, 2014).